Paul J Martin, Stephanie J Lee, Donna Przepiorka, Mary M Horowitz, John Koreth, Georgia B Vogelsang, Irwin Walker, Paul A Carpenter, Linda M Griffith, Gorgun Akpek, Mohamad Mohty, Daniel Wolff, Steven Z Pavletic, Corey S Cutler
Treatment of chronic graft-versus-host disease is intended to produce a sustainable benefit by reducing symptom burden, controlling objective manifestations of disease activity, preventing damage and impairment, and improving overall survival without causing disproportionate harms related to the treatment itself. Successful management can control the disease until systemic treatment is no longer needed. The complexity of the disease, the extended duration of follow-up needed to observe disease resolution and withdrawal of immunosuppressive treatment, and the lack of fully developed shorter term endpoints impede progress in the field...
August 2015: Biology of Blood and Marrow Transplantation